Muzastotug Data Shows Improved Durability

Updated data from a Phase 1b/2 study combining muzastotug with KEYTRUDA® in late-line patients with microsatellite stable colorectal cancer demonstrates improved durability of response. The results indicate a dose-dependent efficacy, with muzastotug achieving a 31% overall response rate in the combined 20 mg/kg cohort. These findings suggest a promising therapeutic benefit for patients with limited treatment options. Further investigation into this combination therapy is warranted to fully assess its potential in treating advanced colorectal cancer.